Endoglin (CD105) expression in human renal cell carcinoma - Wikidata - awgldk - TriplyDB

Endoglin (CD105) expression in human renal cell carcinoma

Endoglin (CD105) expression in human renal cell carcinoma

http://www.wikidata.org/entity/Q58352287

about

TGF-β - an excellent servant but a bad master Targeting Strategies for Renal Cell Carcinoma: From Renal Cancer Cells to Renal Cancer Stem Cells Metastasis-Initiating Cells in Renal Cancer.Functional significance of CD105-positive cells in papillary renal cell carcinoma.Tumoral CD105 is a novel independent prognostic marker for prognosis in clear-cell renal cell carcinoma In search of a better crystal ball: recent advances in prognostic markers for clear-cell renal cell carcinoma.Transforming Growth Factor-β and Endoglin Signaling Orchestrate Wound Healing Prognostic impact of carbonic anhydrase IX expression in human renal cell carcinoma.Biomarkers of Renal Tumors: the Current State and Clinical Perspectives.Microvascular density as an independent predictor of clinical outcome in renal cell carcinoma: an automated image analysis study.Cancer stem cell markers predict a poor prognosis in renal cell carcinoma: a meta-analysis.Lack of association of microvessel density with prognosis of renal cell carcinoma: evidence from meta-analysis.Bevacizumab alone or in combination with TRC105 for patients with refractory metastatic renal cell cancer.Organ-specific endoglin (CD105) expression in the angiogenesis of human cancers.Expression of CD105 cancer stem cell marker in three subtypes of renal cell carcinoma.Endoglin (CD105) expression in the human heart throughout gestation: an immunohistochemical study.Expression of CK19, CD105 and CD146 are associated with early metastasis in patients with renal cell carcinoma.

P2860

Q27025590-BAA881F2-8EB7-4924-B1C9-76CBEEA01CC1 Q28078154-813025ED-46A4-4C24-AE23-17F08EB822E7 Q34077268-E2B05C2E-FD41-4692-83D5-AFAB8E6B6B87 Q36241043-BF730A8B-E7D2-4848-B1A5-F152EC86AAE7 Q37681761-935B5550-0C7B-4FF6-A9BC-9A9701309EAD Q37765585-6BDFDF62-059E-418F-8CB0-B9195CBEC68D Q37967810-27B99551-D215-4BFF-A0A9-42DBD9C5BAB6 Q38431510-FE4381D7-2ECF-4A6B-8DC6-AD75990C11E3 Q39097822-7BBBBD7D-CBB2-4B4B-A040-225F5537F2F7 Q40005099-0E0FB013-8965-41AC-BDF6-5640BE092C82 Q42320212-D4EB4970-76A3-4812-868C-1E0EC30DA068 Q44667014-1BD9040A-B489-411C-835D-47763317EFD2 Q46290452-A0FA9C48-70E1-45BD-915C-581F2A8413F4 Q48374164-FC1B58D6-9C00-4AD2-B0D3-F93292838CB1 Q49494124-2DCF9755-0068-4136-9EA9-6CD05DA5507B Q51944540-E9B0823D-3BB0-4713-871D-ABFD0BDC8F48 Q55224174-A4154220-E808-47F3-B395-BDA4698D0B05

P2860

Endoglin (CD105) expression in human renal cell carcinoma

http://www.wikidata.org/entity/Q58352287

description

im April 2006 veröffentlichter wissenschaftlicher Artikel

@de

наукова стаття, опублікована у квітні 2006

@uk

name

Endoglin (CD105) expression in human renal cell carcinoma

@en

type

label

Endoglin (CD105) expression in human renal cell carcinoma

@en

prefLabel

Endoglin (CD105) expression in human renal cell carcinoma

@en

P1433

Q58352287-4CAFE825-75D5-4826-AECA-0E51C39E8086

P1476

Q58352287-5A549F81-4AEA-4434-AD22-771ED07AFB36

P2093

Q58352287-2BF41C87-4306-4CCE-A9BF-06B620AE3BE6

Q58352287-7234C6B8-F94E-4636-9B8C-8B0100B02DC9

Q58352287-C1B02AF4-DDA5-46DF-8B15-E0F3715C773D

Q58352287-DB9C54E3-B608-4769-AF96-86714770DF9C

P2860

Q58352287-19D39489-E1DE-47A7-92A6-1019E6477ED1

Q58352287-1F764AD4-ECFB-4AFC-94D2-AB568F5D3587

Q58352287-270DF02D-642F-45CE-8BE8-4A02F3EBF76E

Q58352287-36E04079-883F-4C06-8B70-73D8FBBA31D8

Q58352287-5EAE67D0-2674-477A-9869-CE391DEDD1EF

Q58352287-613B72AD-D003-4790-AFD8-BAEC584A618B

Q58352287-9FF7AC07-AA39-4BA0-BD50-1C09B5F733A5

Q58352287-AA4556B9-8A0E-4874-954C-B58D9D16F837

Q58352287-B8366AE0-31C9-4717-8A6E-E336CBD709BF

Q58352287-CD163BE1-C157-4F74-B6BC-115FAE1C54A4

P304

Q58352287-DE648510-A444-4CC8-A9F3-4E5A43D31D3E

P31

Q58352287-E0DA5AB2-AB6C-459C-877B-C5EFFABAC970

P356

Q58352287-304FB5F5-503D-42B7-8D0F-A6240ADC6524

P433

Q58352287-034A0E61-33CB-4168-B00C-D23EC9BC7665

P478

Q58352287-8773FBC7-19CB-410E-A2AB-FF215CD34222

P50

Q58352287-3180579B-876D-43BD-9FDA-7987BA1EE09D

Q58352287-FCC8662C-1D33-459C-B628-A75C9BC1F080

P577

Q58352287-D38C8473-2176-4592-AA57-62B78685D0F4

P698

Q58352287-2D0BB774-1606-4765-A78B-B8A5A7CA31E1

P356

J.1464-410X.2006.06006.X

P1433

BJU International

P1476

Endoglin (CD105) expression in human renal cell carcinoma

@en

P2093

ANDERS BERGH

http://www.w3.org/2001/XMLSchema#string

JOHANNA SANDLUND

http://www.w3.org/2001/XMLSchema#string

TORGNY RASMUSON

http://www.w3.org/2001/XMLSchema#string

YLVA HEDBERG

http://www.w3.org/2001/XMLSchema#string

P2860

Endoglin, a TGF-beta binding protein of endothelial cells, is the gene for hereditary haemorrhagic telangiectasia type 1

Expression of cyclin D1, D3, E, and p27 in human renal cell carcinoma analysed by tissue microarray

Defective angiogenesis in mice lacking endoglin

Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis

Hypoxia--a key regulatory factor in tumour growth

Microvessel density in renal cell carcinoma: lack of prognostic significance.

Endoglin expression is regulated by transcriptional cooperation between the hypoxia and transforming growth factor-beta pathways.

Significance of CD 105 expression for tumour angiogenesis and prognosis in endometrial carcinomas.

Evaluation of microvessel density by computerised image analysis in human renal cell carcinoma. Correlation to pT category, nuclear grade, proliferative activity and occurrence of metastasis.

Expression of vascular endothelial growth factor protein in human renal cell carcinoma

P304

706-710

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/J.1464-410X.2006.06006.X

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

97

http://www.w3.org/2001/XMLSchema#string

P50

Kjell Grankvist

Börje Ljungberg

P577

2006-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

16536758

http://www.w3.org/2001/XMLSchema#string